Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL935224 | 0.78 | CES2 (0.43) | SRCCES2CES1TRPA1KEAP1 | |
| SCHEMBL16604556 | 0.77 | SRC (0.41) | HTR6SRCKEAP1ALDH1A1KDM4E | |
| SCHEMBL2020687 | 0.77 | ALDH1A1 (0.44) | SRCTRPA1KEAP1ALDH1A1KDM4E | |
| SCHEMBL1272692 | 0.77 | CYP2C19 (0.48) | HTR6SRCTRPA1KEAP1ALDH1A1 | |
| SCHEMBL27390102 | 0.75 | SRC (0.56) | HTR6SRCCES2CES1ALDH1A1 | |
| SCHEMBL6593245 | 0.75 | CA1 (0.44) | HTR6SRCCES2CES1ALDH1A1 | |
| SCHEMBL5555050 | 0.73 | SRC (0.39) | SRCKEAP1ALDH1A1KDM4EGMNN | |
| SCHEMBL6633923 | 0.73 | SRC (0.39) | SRCKEAP1ALDH1A1KDM4EGMNN | |
| SCHEMBL2360079 | 0.73 | DPP4 (0.46) | SRCALDH1A1KDM4ELMNACYP2D6 | |
| SCHEMBL5200608 | 0.73 | TSHR (0.46) | SRCKEAP1ALDH1A1KDM4EGMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200239490-A1 | PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-07-30 | — | — | US | claimed |
| EP-3642200-A1 | PYRIDINE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2020-04-29 | — | — | EP | claimed |
| CN-110753690-A | Pyridine derivatives | 豪夫迈·罗氏有限公司 | 2020-02-04 | — | — | CN | claimed |
| WO-2018234284-A1 | PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-12-27 | — | — | WO | claimed |
| EP-2731436-B1 | 2-(PYRROLO[2,3-B]PYRIDINE-5-YL)-2-(T-BUTOXY)-ACETIC ACID DERIVATIVES AS HIV REPLICATION INHIBITORS FOR THE TREATMENT OF AIDS | VIIV HEALTHCARE UK LTD (GB) | 2017-03-08 | — | — | EP | claimed |
| US-9163023-B2 | Compounds and methods for treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2015-10-20 | — | — | US | claimed |
| US-20150191469-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2015-07-09 | — | — | US | claimed |
| EP-2877468-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | VIIV Healthcare UK Limited (GB) | 2015-06-03 | — | — | EP | claimed |
| US-9029391-B2 | Isoquinoline compounds and methods for treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2015-05-12 | — | — | US | claimed |
| EP-2731436-A1 | AZAINDOLE COMPOUNDS AND METHODS FOR TREATING HIV | VIIV Healthcare UK Limited (GB) | 2014-05-21 | — | — | EP | claimed |
| WO-2014009794-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2014-01-16 | — | — | WO | claimed |
| US-8609653-B2 | Azaindole compounds and methods for treating HIV | GLAXOSMITHKLINE LLC (US) | 2013-12-17 | — | — | US | claimed |
| US-20130289027-A1 | Isoquinoline Compounds And Methods For Treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2013-10-31 | — | — | US | claimed |
| WO-2013012649-A1 | AZAINDOLE COMPOUNDS AND METHODS FOR TREATING HIV | GLAXOSMITHKLINE LLC (US) | 2013-01-24 | — | — | WO | claimed |
| US-20130018049-A1 | Azaindole Compounds and Methods for Treating HIV | GLAXOSMITHKLINE LLC (US) | 2013-01-17 | — | — | US | claimed |
| WO-2012102985-A1 | ISOQUINOLINE COMPOUNDS AND METHODS FOR TREATING HIV | GLAXOSMITHKLINE LLC (US) | 2012-08-02 | — | — | WO | claimed |
| CN-110753690-B | Pyridine derivatives | 豪夫迈·罗氏有限公司 | 2023-12-05 | — | — | CN | disclosed |
| EP-3642200-B1 | PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-05-03 | — | — | EP | disclosed |
| US-4443598-A | ANTIBIOTICS AND INTERMEDIATES | SHIONOGI & CO., LTD. (JP) | 1984-04-17 | — | — | US | disclosed |
| US-4366316-A | FROM OXAZOLINOAZETIDINONE AND ACID | SHIONOGI & CO., LTD. (JP) | 1982-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191469-A1 | COMPOUNDS AND METHODS FOR TREATING HIV | CCR5, CD4, HAVCR2 | HTR6 2530/4885SRC 594/4885CES2 12/4885 |
| US-20130018049-A1 | Azaindole Compounds and Methods for Treating HIV | AZI2, TPMT, INMT | HTR6 479/4885SRC 807/4885CES2 164/4885 |
| US-20200239490-A1 | PYRIDINE DERIVATIVES | NDUFS6, NDUFS3, CYP11B2 | HTR6 723/4885SRC 3238/4885CES2 1262/4885 |
| US-20130289027-A1 | Isoquinoline Compounds And Methods For Treating HIV | MAVS, CCR5, NFATC1 | HTR6 2240/4885SRC 951/4885CES2 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.